background
sever
diseas
caus
pandem
influenza
character
presenc
hypercytokinemia
origin
exacerb
cytokin
respons
unclear
observ
previous
uncontrol
influenza
viru
replic
could
strongli
influenc
cytokin
product
object
present
studi
evalu
relationship
host
cytokin
respons
viral
level
pandem
influenza
critic
ill
patient
method
twenti
three
patient
admit
icu
primari
viral
pneumonia
includ
studi
quantit
pcr
base
method
target
influenza
gene
develop
quantifi
pharyng
viral
load
addit
use
multiplex
base
assay
systemat
evalu
host
cytokin
respons
viral
infect
admiss
icu
correl
studi
cytokin
level
viral
load
done
calcul
spearman
correl
coeffici
result
fifteen
patient
need
intub
ventil
eight
need
mechan
ventil
icu
hospit
viral
load
pharyng
swab
fold
higher
group
patient
worst
respiratori
condit
admiss
icu
pharyng
viral
load
directli
correl
plasma
level
proinflammatori
cytokin
chemotact
factor
gmcsf
angiogen
mediat
vegf
also
immunomodulatori
cytokin
p
correl
studi
demonstr
also
exist
signific
posit
associ
level
mediat
evidenc
simultan
regul
respons
viru
conclus
sever
respiratori
diseas
caus
pandem
influenza
viru
character
exist
direct
associ
viral
replic
host
cytokin
respons
reveal
potenti
pathogen
link
sever
diseas
caus
influenza
subtyp
infect
immun
medic
investig
unit
imi
hospit
universitarioiecscyl
avda
cajal
valladolid
spain
full
list
author
inform
avail
end
articl
background
two
year
later
pathogenesi
ill
caus
pandem
influenza
still
poorli
known
pregnanc
sever
obes
cardiovascular
diseas
diabet
report
risk
factor
critic
ill
follow
infect
pandem
viru
persist
viral
secret
found
patient
worst
outcom
prompt
antivir
treatment
recogn
protect
factor
number
studi
report
increas
persist
level
cytokin
chemokin
parallel
sever
diseas
exacerb
cytokin
respons
contribut
immunemedi
tissu
damag
viral
infect
sens
unregul
cytokin
interferon
respons
describ
parallel
persist
viral
replic
sever
diseas
sar
caus
observ
hypercytokinemia
sever
pandem
influenza
unclear
previous
describ
uncontrol
influenza
viru
replic
could
strongli
influenc
cytokin
product
object
present
studi
evalu
relationship
host
cytokin
respons
pharyng
viral
load
pandem
influenza
critic
ill
patient
admiss
icu
twenti
three
patient
attend
particip
icu
primari
viral
pneumonia
acut
phase
influenza
viru
ill
neg
respiratori
blood
bacteri
cultur
admiss
recruit
novemb
st
decemb
st
patient
confirm
infect
realtim
polymeras
chain
reaction
pcr
includ
studi
blood
sampl
plasma
serum
collect
use
serum
ethylenediaminetetraacet
acid
edta
venou
blood
vacuum
collect
tube
follow
manufactur
instruct
next
hour
follow
admiss
icu
accord
unifi
protocol
particip
center
pharyng
sampl
collect
parallel
fifteen
healthi
volunt
similar
age
patient
recruit
among
worker
univers
valladolid
spain
standard
survey
employ
collect
clinic
data
includ
histori
physic
examin
oximetr
measur
haematolog
biochem
radiolog
microbiolog
investig
particip
center
treatment
decis
patient
standard
decid
attend
physician
inform
consent
obtain
directli
patient
legal
repres
also
healthi
control
enrol
patient
control
identif
remain
anonym
approv
studi
protocol
scientif
ethic
aspect
obtain
scientif
committe
clinic
research
one
particip
center
sampl
store
viral
load
quantif
cytokin
antibodi
profil
patient
split
two
group
depend
sever
respiratori
failur
mv
group
underw
intub
ventil
n
nmv
group
compos
eight
patient
requir
mechan
ventil
icu
hospit
viral
diagnosi
perform
rna
pharyng
swab
microbiolog
servic
particip
hospit
revers
transcriptionpolymeras
chain
reaction
rtpcr
base
method
use
reagent
provid
free
charg
center
diseas
control
cdc
atlanta
ga
usa
purchas
roch
basel
switzerland
detect
set
sampl
also
assess
multiplex
pcr
luminex
xtag
rvp
kit
luminexabbott
coinfect
respiratori
syncyti
viru
influenza
b
viru
parainfluenza
virus
human
metapneumoviru
enterovirus
rhinoviru
adenoviru
bocaviru
coronavirus
accord
manufactur
instruct
viral
load
quantifi
pharyng
swab
plasma
virolog
lab
associ
center
hospit
clinic
barcelona
spain
first
singl
real
time
rtpcr
perform
influenza
viral
load
quantif
set
primer
probe
specif
influenza
viru
matrix
protein
gene
standard
graph
construct
threshold
cycl
valu
obtain
serial
dilut
crna
control
crna
control
manufactur
pcr
product
clone
plasmid
pgemt
easi
vector
system
promega
plasmid
contain
rna
polymeras
promot
upstream
insert
drive
transcript
enzym
previou
vitro
transcrib
use
megascript
kit
ambion
plasmid
linear
restrict
enzym
spei
new
england
biolab
downstream
insert
addit
dnase
treatment
residu
dna
remov
rna
transcript
final
rna
purifi
use
megaclear
kit
ambion
concentr
puriti
rna
control
calcul
measur
known
rna
control
serial
dilut
tenfold
steril
water
use
real
time
pcr
limit
detect
rna
copiesreact
effici
data
shown
oseltamivir
resist
directli
detect
initi
posit
pharyng
swab
rtpcr
sequenc
fragment
neuraminidas
gene
presenc
mutat
use
abi
genet
analyz
standard
respiratori
blood
cultur
perform
assess
presenc
bacteri
fungal
infect
along
detect
urinari
antigen
test
legionella
pneumophila
streptococcu
pneumonia
hai
assay
perform
aliquot
sampl
univers
health
network
uhn
toronto
ontario
canada
previous
describ
use
inactiv
pandem
influenza
antigen
immun
mediat
level
plasma
measur
patient
control
use
multiplex
biorad
assay
hercul
ca
usa
infect
immun
medic
investig
unit
imi
hcuviecscyl
valladolid
spain
system
allow
quantit
measur
differ
chemokin
cytokin
growth
factor
immun
mediat
consum
small
amount
biolog
materi
number
addit
solubl
mediat
measur
use
enzymelink
inmunosorb
assay
elisa
verikin
kit
purchas
pbl
interferon
sourc
piscataway
nj
usa
quantikin
kit
purchas
r
system
minneapoli
mn
usa
legend
max
kit
purchas
biolegend
san
diego
ca
usa
immun
mediat
concentr
individu
sampl
normal
median
concentr
control
group
n
result
ratio
compar
group
patient
mannwhitney
u
test
employ
cytokin
comparison
purpos
sinc
saphiro
wilk
test
evidenc
absenc
normal
distribut
data
leven
test
demonstr
absenc
homogen
varianc
mv
nmv
group
correl
studi
cytokin
level
viral
load
clinic
paramet
done
calcul
spearman
correl
coeffici
fisher
exact
test
employ
compar
proport
fatal
case
patient
receiv
steroid
statist
test
twosid
p
consid
signific
clinic
data
tabl
chronic
respiratori
diseas
smoke
frequent
accompani
medic
condit
cohort
three
women
pregnant
one
undergo
second
trimest
pregnanc
two
third
one
patient
admit
icu
five
day
averag
follow
onset
symptom
group
patient
mv
group
show
sever
respiratori
statu
admiss
base
pa
valu
sofa
score
appear
bilater
infiltr
chest
xray
common
find
group
mv
nmv
patient
show
elev
level
ast
cpk
first
contact
critic
care
servic
lymphopenia
observ
three
mv
patient
one
nmv
patient
receiv
antivir
treatment
oseltamivir
upon
admiss
icu
six
fifteen
mv
patient
receiv
steroid
treatment
first
hour
follow
admiss
icu
six
eight
patient
nmv
group
alreadi
mention
patient
show
clinic
microbiolog
sign
bacteri
infect
admiss
icu
bacteri
super
infect
hospit
period
observ
four
fifteen
mv
patient
patient
nmv
group
suffer
bacteri
infect
hospit
base
hemagglutin
inhibit
assay
hai
four
patient
two
mv
two
nmv
develop
specif
antibodi
pandem
influenza
time
admiss
icu
mv
patient
stay
longer
icu
nmv
patient
seven
mv
patient
final
die
nmv
patient
surviv
differ
found
proport
fatal
case
patient
receiv
earli
treatment
steroid
n
fatal
case
receiv
treatment
n
fatal
case
p
last
three
valu
correspond
three
patient
eventu
die
nmv
patient
detect
viru
plasma
show
viral
load
copiesml
found
signific
correl
viral
rna
load
plasma
apach
ii
sever
score
admiss
mutat
neuraminidas
gene
na
found
one
sampl
collect
mv
male
patient
receiv
oseltamivir
h
three
day
icu
admiss
patient
final
die
ten
day
onset
symptom
six
day
admiss
icu
partial
na
sequenc
upload
genbank
databas
access
number
haemagglutinin
ha
mutat
detect
viral
sampl
obtain
five
fifteen
sever
patient
three
case
show
variat
show
detect
viru
plasma
one
final
die
two
fatal
case
show
mutat
one
show
detect
viru
plasma
nmv
group
one
patient
show
variat
mv
patient
viral
mutat
show
differ
pharyng
viral
load
compar
mv
patient
mutat
absent
comparison
cytokin
profil
show
significantli
higher
level
three
chemokin
two
cellular
growth
factor
vegf
gmcsf
two
immunomodulatori
cytokin
mv
group
compar
nmv
one
figur
addit
mv
patient
show
also
higher
level
two
cytokin
cytokin
p
mv
nmv
patient
figur
correl
analysi
also
demonstr
associ
viral
load
level
p
associ
plasma
level
vegf
gmcsf
examin
signific
posit
correl
found
except
pair
form
data
shown
relationship
influenza
viru
earli
host
immun
respons
could
determin
clinic
outcom
present
studi
patient
sever
observ
absenc
specif
antibodi
pandem
viru
vast
major
patient
studi
could
explain
fail
control
viral
replic
lack
protect
antibodi
new
viru
indic
patient
still
undergo
innat
phase
host
respons
viru
moment
sampl
sens
import
highlight
cohort
constitut
non
vaccin
individu
observ
somehow
remark
potenti
import
vaccin
prevent
sever
influenza
diseas
ten
patient
studi
pertain
previou
cohort
cytokin
profil
along
period
time
compris
diseas
onset
moment
appear
specif
antibodi
viru
low
number
patient
avail
inclus
period
sampl
mv
patient
sampl
nmv
patient
preclud
perhap
obtain
signific
differ
patient
differ
degre
respiratori
involv
occas
nonetheless
consequ
found
ventil
patient
higher
level
mediat
describ
present
articl
new
work
studi
larger
cohort
patient
n
cytokin
profil
compar
punctual
moment
diseas
cours
admiss
icu
approach
evidenc
admiss
sever
patient
mv
show
exuber
cytokin
chemokin
respons
conson
previou
report
turn
new
work
aim
analyz
relationship
viral
replic
host
cytokin
respons
sens
strike
find
occur
human
case
influenza
infect
pandem
influenza
viru
replic
directli
associ
host
cytokin
respons
point
central
role
viral
burden
pathogenesi
sever
form
diseas
correl
studi
reveal
also
pro
anti
inflammatori
cytokin
simultan
regul
respons
viru
gmcsf
chemotact
molecul
mobil
neutrophil
monocyt
macrophag
site
infect
critic
contributor
adapt
immun
especi
helper
type
respons
report
along
marker
critic
pandem
influenza
ill
vegf
potent
angiogen
factor
stimul
hypox
patient
addit
thought
increas
permeabl
bronchial
airway
epithelium
follow
infect
respiratori
virus
mediat
proinflammatori
consequ
could
play
role
genesi
respiratori
failur
patient
altern
could
neccesari
overcom
influenza
infect
sever
patient
immunomodulatori
molecul
secret
could
repres
attempt
prevent
cytokinedriven
inflammatori
damag
altern
repres
virusinduc
evas
mechan
turn
elev
level
cytokin
could
interfer
develop
appropri
adapt
immun
respons
viru
result
confirm
critic
ill
patient
previou
result
obtain
lee
et
al
hospit
patient
pandem
influenza
demonstr
high
plasma
level
correl
extent
progress
pneumonia
condit
pregnanc
obes
chronic
respiratori
diseas
could
influenc
cytokin
product
respons
viral
infect
moreov
mechan
ventil
induc
proinflammatori
state
patient
steroid
treatment
could
downmodul
cytokin
respons
also
fact
seem
occur
cohort
nonetheless
detriment
effect
steroid
document
sever
pandem
influenza
associ
increas
risk
bacteri
superinfect
treat
patient
contrari
steroid
treatment
impact
pharyng
viral
load
least
time
sampl
cohort
fact
patient
treat
begun
antivir
treatment
time
sampl
tabl
could
also
explain
exacerb
cytokin
respons
observ
patient
one
third
sever
patient
show
amino
acid
substitut
ha
viru
thought
confer
increas
predilect
viru
lower
respiratori
tract
associ
case
sever
diseas
sinc
one
sever
patient
infect
viru
contain
mutat
na
gene
potenti
influenc
oseltamivir
resist
outcom
patient
limit
though
singl
patient
infect
mutant
viru
fatal
outcom
conclus
sever
respiratori
diseas
caus
pandem
influenza
viru
character
exist
direct
associ
viral
replic
host
cytokin
respons
reveal
potenti
pathogen
link
sever
diseas
caus
influenza
subtyp
list
abbrevi
gmcsf
granulocyt
macrophag
colonystimul
factor
ifn
interferon
il
interleukin
interleukin
receptor
antagonist
interferongamma
induc
monocyt
chemoattract
macrophag
inflammatori
mv
mechan
ventil
nmv
non
mechan
ventil
tgfb
transform
growth
factor
beta
vegf
vascular
endotheli
growth
factor
